Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2015

Katayama Ryohei, Kobayashi Yuka, Friboulet Luc, Lockerman Elizabeth L, Koike Sumie, Shaw Alice T, Engelman Jeffrey A, Fujita Naoya

Abstract excerpt

PURPOSE: ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non-small cell lung cancer (NSCLC) harboring ROS1 fusions; however, cancers eventually develop crizotinib resistance due to acquired mutations such as G2032R in ROS1. Thus,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Antigens, Differentiation, B-Lymphocyte

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Histocompatibility Antigens Class II

Share to Oncogene Proteins, Fusion

Share to Protein-Tyrosine Kinases

Share to Pyrazoles

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 25351743
DOI: 10.1158/1078-0432.CCR-14-1385
PMCID: PMC4286456

Genes

ROS1
ALK
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.PMID 25351743Read ↗

Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.Semantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.Semantic proximity Read ↗

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.Semantic proximity Read ↗

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsSemantic proximity Read ↗

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.Semantic proximity Read ↗

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.Semantic proximity Read ↗

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive CancersSemantic proximity Read ↗

Acquired resistance to crizotinib from a mutation in CD74-ROS1.Semantic proximity Read ↗

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.Semantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.